Substituted 4-aminocyclohexanols

Details Substituted 4-aminocyclohexanols Substituted 4-aminocyclohexanols

2007-02-27

2007-02-27

Davis, Brian (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C548S179000, C548S469000, C549S058000, C549S341000, C549S469000, C514S367000, C514S415000, C514S443000, C514S462000, C514S469000, C514S647000

Reexamination Certificate

active

10758242

ABSTRACT:
Substituted 4-aminocyclohexanols, methods of producing the same, pharmaceuticals containing these compounds, the use of substituted 4-aminocyclohexanols for producing pharmaceutical compositions for the treatment of various indications, in particular pain, and for related treatment methods.

REFERENCES:
patent: 4115589 (1978-09-01), Lednicer
patent: 4212878 (1980-07-01), Lednicer et al.
patent: 4346101 (1982-08-01), Lednicer
patent: 4366172 (1982-12-01), Lednicer
patent: 5239110 (1993-08-01), Mallamo et al.
patent: 5304479 (1994-04-01), Lin
patent: 2839891 (1979-04-01), None
patent: 19963175 (2001-07-01), None
patent: 0410191 (1991-01-01), None
patent: WO 01/12195 (2001-02-01), None
Database CAPLUS on STN, Acc. No. 1987:423027, Swahn et al., Report (1985), FOA-C-40220-C1; Order No. PB86-129921/GAR, 21 pp. Avail.:NTIS From: Gov. Rep. Announce. Index (US) 1986, 86(7), Abstract No. 613-507 (abstract).
Daniel Lednicer et al., “4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol, an Extremely Potent Representative of a New Analgesic Series”, Journal of Medicinal Chemistry, Oct. 1979, pp. 1157-1158, vol. 22, No. 10, American Chemical Society.
Hiroshi Kawamoto et al., “Synthesis of J-113397, the First Potent and Selective ORL1 Antagonist,” Tetrahedron, 2001, pp. 981-986, 57, Elsevier Science Ltd.
Faud A. Abdulla et al., “Axotomy Reduces the Effect of Analgesic Opioids Yet Increases the Effect of Nociceptin on Dorsal Root Ganglion Neurons,” The Journal of Neuroscience, Dec. 1, 1998, pp. 9685-9694, 18, 23, Society for Neuroscience.
Girolamo Calo et al., “Pharmacology of Nociceptin and its Receptor: A Novel Therapeutic Target,” British Journal of Pharmacology, 2000, pp. 1261-1283, 129, Macmillan Publishers Ltd.
Mark Conner et al., “The Effect of Nociceptin on Ca2+Channel Current and Intracellular Ca2+in the SH-SY5Y Human Neuroblastoma Cell Line”, 1996, pp. 205-207, 118, Stockton Press.
E.S.L. Faber et al., “Depression of Glutamatergic Transmission by Nociceptin in the Neonatal Rat Hemisected Spinal Cord PreparationIn Vitro”, Special Report, Jul. 19, 1996, pp. 1-2.
“Opioid and Opiate Receptors: Peptides and Knock-Out,” Society for Neuroscience, 1998, p. 1358, vol. 24.
Francois Jenck et al., “Orphanin FQ Acts as an Anxiolytic to Attenuate Behavioral Responses to Stress,” Proc. Natl. Acad. Sci., Dec. 1997, pp. 14854-14858, vol. 94, USA.
Michael A. King et al., “Spinal Analgesic Activity of Orphanin FQ/Nociceptin and its Fragments”, Neuroscience Letters, 1997, pp. 113-116, 223, Elsevier Science Ireland Ltd.
Toshiya Manabe et al., “Facilitation of Long-Term Potentiation and Memory in Mice Lacking Nociceptin Receptors”, Letters To Nature, Aug. 6, 1998, pp. 577-581, vol. 394, Macmillan Publishers Ltd.
Jean-Claude Meunier et al., “Isolation and Structure of the Endogenous Agonist of Opiod Receptor-Like ORL1Receptor,” Letters to Nature, Oct. 12, 1995, pp. 532-535, vol. 377.
J.S. Mogil et al., “Orphanin FQ is a Functional Anti-Opioid Peptide”, Neuroscience, 1996, pp. 333-337, vol. 75, No. 2, Elsevier Science Ltd., Great Britain.
Miyuki Nishi et al., “Unrestrained Nociceptive Response and Disregulation of Hearing Ability in Mice Lacking the Nociceptin/OrphaninFQ Receptor,” The EMBO Journal, 1997, pp. 1858-1864, vol. 16, No. 8, Oxford University Press.
Rainer K. Reinscheid et al., “Orphanin FQ: A Neuropeptide That Activates an Opioldlike G Protein-Coupled Receptor,” Science, Nov. 3, 1995, pp. 792-794, vol. 270.
Christopher W. Vaughan et al., “Increase by the ORL1Receptor (Opioid Receptor-like1) Ligand, Nociceptin, of Inwardly Rectifying K Conductance in Dorsal Raphe Nucleus Neurones,” Special Report, pp. 1609-1611.
Tatsuo Yamamoto et al., “Effects of Intrathecally Administered Nociceptin, an Opioid Receptor-like1Receptor Agonist, and N-methyl-D-aspartate Receptor Antagonist on the Thermal Hyperalgesia Induced by Partial Sciatic Nerve Injury in the Rat,” Anesthesiology, 1997, pp. 1145-1152, vol. 87, No. 5, Lippincott-Raven Publishers.
Ali Ardati et al., “Interaction of [3H]Orphanin FQ and125I-Tyr14-Orphanin FQ with the Orphanin FQ Receptor: Kinetics and Modulation by Cations and Guanine Nucleotides,” Molecular Pharmacology, 1997, pp. 816-824, 51, The American Society for Pharmacology and Experimental Therapeutics.
Hunter C. Champion et al., “[Tyr1]-Nociceptin, a Novel Nociceptin Analog, Decreases Systemic Arterial Pressure by a Naloxone-Insensitive Mechanism in the Rat,” Biochemical and Biophysical Research Communications, 1997, pp. 309-312, 234, Academic Press.
Tristan Darland et al., “Orphanin FQ
ociceptin: a Role in Pain and Analgesia, But So Much More,” TINS, 1998, pp. 215-221, vol. 21, No. 5, Elsevier Science Ltd.
Bulent Gumusel et al., “Nociceptin: An Endogenous Agonist for Central Opioid Like1(ORL1) Receptors Possesses Systemic Vasorelaxant Properties,” Life Sciences, 1997, pp. PL 141-145, vol. 60, No. 8, Elsevier Science Inc., USA.
Naoki Hara et al., “Characterization of Nociceptin Hyperalgesia and Allodynia in Conscious Mice,” British Journal of Pharmacology, 1997, pp. 401-408, 121, Stockton Press.
Daniel R. Kapusta et al., “Diuretic and Antinatriuretic Responses Produced by the Endogenous Opioid-Like Peptide, Nociceptin (Orphanin FQ),” Life Sciences, 1997, pp. PL 15-21, vol. 60, No. 1, Elsevier Science Inc., USA.
Frederic Knoflach et al., “Modulation of Voltage-Gated Calcium Channels by Orphanin FQ in Freshly Hippocampal Neurons,” The Journal of Neuroscience, Nov. 1, 1996, pp. 6657-6664, 16, 21, Society for Neuroscience.
Hans Matthes et al., “Functional Selectivity of Orphanin FQ for Its Receptor Coexpressed with Potassium Channel Subunits in XenopuslaevisOocytes,” Molecular Pharmacology, 1996, pp. 447-450, 50, The American Society for Pharmacology and Experimental Therapeutics.
Jeffrey S. Mogil et al., “Functional Antagonism of μ-, Σ- and Θ-opioid Antinociception by Orphanin FQ,” Neuroscience Letters, 1996, pp. 131-134, 214, Elsevier Science Ireland Ltd.
Catherine Mollereau et al., “ORL1, A Novel Members of the Opioids Receptor Family Cloning, Functional Expression and Localization,” FEBS Letters, 1994, 341, Federation of European Biochemical Societies.
James D. Pomonis et al., “Orphanin FQ, Agonist of Orphan Opioid Receptor ORL1, Stimulates Feeding in Rats,” NeuroReport, Dec. 20, 1996, pp. 369-371, vol. 8, No. 1, Rapid Science Publishers.
Y.-S. Shu et al., “Orphanin FQ/Nociceptin Modulates Glutamate- and Kainic Acid-Induced Currents in Acutely Isolated Rat Spinal Dorsal Horn Neurons,” Neuropeptides, 1998, pp. 567-571, 32, Harcourt Brace & Co., Ltd.
Xiao-Jun Xu et al., “Nociceptin or Antinociceptin: Potent Spinal Antinociceptive Effect of Orphanin FQ/ Nociceptin in the Rat,” NeuroReport, Sep. 2, 1996, vol. 17, No. 13, Rapid Science Publishers.
T. Yamamoto et al., “Analgesic Effect of Intrathecally Administered Nociceptin, an Opioid Receptor-Like1Receptor Agonist, in the Rat Formalin Test,” Neuroscience, 1997, pp. 249-254, vol. 81, Elsevier Science Ltd.
M.N.A. Rao et al., “Quantitative Correlation Between Hydrophobicity and Analgesis Activity of 4-Amino 4-Arylcyclohexanols,” Indian Drugs, 1985, pp. 252-257, 22, 5.
Jean-Marc Kamenka et al., “Orientation Structurale et Conformationnelle de la Fixation de la Phencyclidine dans le SNC,” Eur. J. Med. Chem. 1984, pp. 255-260, 19, 3.
Daniel Lednicer et al., “4-Amino-4-arylclohexanones and Their Derivatives, a Novel Class of Analgestics”, J. Med. Chem., 1980, pp. 424-430, 23.
Von Voigtlander et al., “4-Aryl-4-Aminocyclohexanone Derivatives: A Chemically Novel Series of Analgesics Including Opioid Antagonists and Extremely Potent Agonists,”Endog. Exo

Affiliated with

Also associated with

Rating

Substituted 4-aminocyclohexanols does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 4-aminocyclohexanols, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-aminocyclohexanols will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3838869